Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients

Journal of Immunology

Volumn 183, Issue 10, 2009, Pages 6338-6345

  Collarini, Ellen J ^a   Lee, F Eun Hyung ^b   Foord, Orit ^a   Park, Minha ^a   Sperinde, Gizette ^a   Wu, Hai ^a   Harriman, William D ^a   Carroll, Stephen F ^a   Ellsworth, Stote L ^a   Anderson, Larry J ^c   Tripp, Ralph A ^d   Walsh, Edward E ^b   Keyt, Bruce A ^a   Kauvar, Lawrence M ^a  

^a Trellis Bioscience   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; PALIVIZUMAB; PROTEIN F; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS LOAD; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIGENS, VIRAL; B-LYMPHOCYTES; CELL LINE; HUMANS; MICE; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TRANSFECTION; VIRAL FUSION PROTEINS; VIRAL LOAD;

EID: 77954230121     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901373     Document Type: Article

References (52)

1. Hall, C. B., G. A. Weinberg, M. K. Iwane, A. K. Blumkin, K. M. Edwards, M. A. Staat, P. Auinger, M. R. Griffin, K. A. Poehling, D. Erdman, et al. 2009. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360: 588-598.
2. Falsey, A. R., P. A. Hennessey, M. A. Formica, C. Cox, and E. E. Walsh. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352: 1749-1759.
3. Ison, M. G. 2007. Respiratory viral infections in transplant recipients. Antivir. Ther. 12: 627-638. (Pubitemid 47235505)
4. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson, and K. Fukuda. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
5. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89: 405-421.
6. IMpact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531-537.
7. Wu, H., D. S. Pfarr, S. Johnson, Y. A. Brewah, R. M. Woods, N. K. Patel, W. I. White, J. F. Young, and P. A. Kiener. 2007. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368: 652-665.
8. Saez-Llorens, X., M. T. Moreno, O. Ramilo, P. J. Sanchez, F. H. Top, Jr., and E. M. Connor. 2004. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 23: 707-712.
9. Ventre, K., and A. G. Randolph. 2007. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst. Rev. CD000181.
10. Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus. In Virology. B. N. Fields, D. M. Knipe, and P. M. Howley, eds. Lippincott-Raven, Philadephia, PA, pp. 1313-1351.
11. Anderson, L. J., J. C. Hierholzer, C. Tsou, R. M. Hendry, B. F. Fernie, Y. Stone, and K. McIntosh. 1985. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J. Infect. Dis. 151: 626-633. (Pubitemid 15102158)
12. Wertz, G. W., and R. M. Moudy. 2004. Antigenic and genetic variation in human respiratory syncytial virus. Pediatr. Infect. Dis. J. 23: S19-S24.
13. Roberts, S. R., D. Lichtenstein, L. A. Ball, and G. W. Wertz. 1994. The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J. Virol. 68: 4538-4546.
14. Johnson, P. R., M. K. Spriggs, R. A. Olmsted, and P. L. Collins. 1987. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc. Natl. Acad. Sci. USA 84: 5625-5629.
15. Tripp, R. A., L. P. Jones, L. M. Haynes, H. Zheng, P. M. Murphy, and L. J. Anderson. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2: 732-738.
16. Oshansky, C. M., W. Zhang, E. Moore, and R. A. Tripp. 2009. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 4: 279-297.
17. Becker, Y. 2006. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy: a review. Virus Genes 33: 235-252.
18. Gonzalez, P. A., C. E. Prado, E. D. Leiva, L. J. Carreno, S. M. Bueno, C. A. Riedel, and A. M. Kalergis. 2008. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc. Natl. Acad. Sci. USA 105: 14999-15004.
19. Arnold, R., B. Konig, H. Werchau, and W. Konig. 2004. Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology 330: 384-397.
20. Bukreyev, A., L. Yang, J. Fricke, L. Cheng, J. M. Ward, B. R. Murphy, and P. L. Collins. 2008. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82: 12191-12204.
21. + T cell responses. J. Immunol. 176: 1600-1608.
22. Maher, C. F., T. Hussell, E. Blair, C. J. Ring, and P. J. Openshaw. 2004. Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect. 6: 1049-1055.
23. Polack, F. P., P. M. Irusta, S. J. Hoffman, M. P. Schiatti, G. A. Melendi, M. F. Delgado, F. R. Laham, B. Thumar, R. M. Hendry, J. A. Melero, et al. 2005. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc. Natl. Acad. Sci. USA 102: 8996-9001.
24. Shingai, M., M. Azuma, T. Ebihara, M. Sasai, K. Funami, M. Ayata, H. Ogura, H. Tsutsumi, M. Matsumoto, and T. Seya. 2008. Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-β induction. Int. Immunol. 20: 1169-1180.
25. Tripp, R. A., D. Moore, L. Jones, W. Sullender, J. Winter, and L. J. Anderson. 1999. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 73: 7099-7107.
26. Tripp, R. A. 2004. Pathogenesis of respiratory syncytial virus infection. Viral Immunol. 17: 165-181.
27. Tal, G., A. Mandelberg, I. Dalal, K. Cesar, E. Somekh, A. Tal, A. Oron, S. Itskovich, A. Ballin, S. Houri, et al. 2004. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J. Infect. Dis. 189: 2057-2063.
28. Cepika, A. M., A. Gagro, A. Bace, D. Tjesic-Drinkovic, J. Kelecic, T. Baricic-Voskresensky, M. Matic, V. Drazenovic, I. Marinic, G. Mlinaric-Galinovic, Z. Vrtar, and S. Rabatic. 2008. Expression of chemokine receptor CX3CR1 in infants with respiratory syncytial virus bronchiolitis. Pediatr. Allergy Immunol. 19: 148-156.
29. Mekseepralard, C., G. L. Toms, and E. G. Routledge. 2006. Protection of mice against human respiratory syncytial virus by wild-type and aglycosyl mouse-human chimaeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein. J Gen. Virol. 87: 1267-1273.
30. Walsh, E. E., C. B. Hall, J. J. Schlesinger, M. W. Brandriss, S. Hildreth, and P. Paradiso. 1989. Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins. J. Gen. Virol. 70(Pt 11): 2953-2961.
31. Haynes, L. M., H. Caidi, G. U. Radu, C. Miao, J. Harcourt, R. A. Tripp, and L. J. Anderson. 2009. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus G protein mediates virus clearance and reduces RSV pathogenesis in BALB/c mice. J. Infect. Dis. 200: 439-447.
32. Miao, C., G. U. Radu, H. Caidi, R. A. Tripp, L. J. Anderson, and L. M. Haynes. 2009. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediate reduced pulmonary inflammation in mice. J Gen. Virol. 90(Pt 5): 1119-1123.
33. Traggiai, E., S. Becker, K. Subbarao, L. Kolesnikova, Y. Uematsu, M. R. Gismondo, B. R. Murphy, R. Rappuoli, and A. Lanzavecchia. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10: 871-875.
34. Wrammert, J., K. Smith, J. Miller, W. A. Langley, K. Kokko, C. Larsen, N. Y. Zheng, I. Mays, L. Garman, C. Helms, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671.
35. Harriman, W. D., E. J. Collarini, G. V. Sperinde, M. Strandh, M. M. Fatholahi, A. Dutta, Y. Lee, S. E. Mettler, B. A. Keyt, S. L. Ellsworth, and L. M. Kauvar. 2009. Antibody discovery via multiplexed single cell characterization. J. Immunol. Methods 341: 135-145.
36. Deml, L., A. Bojak, S. Steck, M. Graf, J. Wild, R. Schirmbeck, H. Wolf, and R. Wagner. 2001. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J. Virol. 75: 10991-11001.
37. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
38. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76: 4350-4354. (Pubitemid 9256559)
39. Tang, R. S., M. MacPhail, J. H. Schickli, J. Kaur, C. L. Robinson, H. A. Lawlor, J. M. Guzzetta, R. R. Spaete, and A. A. Haller. 2004. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J. Virol. 78: 11198-11207.
40. Falsey, A. R., H. K. Singh, and E. E. Walsh. 2006. Serum antibody decay in adults following natural respiratory syncytial virus infection. J. Med. Virol. 78: 1493-1497.
41. Chong, Y., H. Ikematsu, K. Yamaji, M. Nishimura, S. Kashiwagi, and J. Hayashi. 2003. Age-related accumulation of Ig V(H) gene somatic mutations in peripheral B cells from aged humans. Clin. Exp. Immunol. 133: 59-66.
42. Amit, A. G., R. A. Mariuzza, S. E. Phillips, and R. J. Poljak. 1986. Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution. Science 233: 747-753. (Pubitemid 16016225)
43. Tian, C., G. K. Luskin, K. M. Dischert, J. N. Higginbotham, B. E. Shepherd, and J. E. Crowe, Jr. 2008. Immunodominance of the VH1-46 antibody gene segment in the primary repertoire of human rotavirus-specific B cells is reduced in the memory compartment through somatic mutation of nondominant clones. J. Immunol. 180: 3279-3288.
44. Carbonari, M., E. Caprini, T. Tedesco, F. Mazzetta, V. Tocco, M. Casato, G. Russo, and M. Fiorilli. 2005. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J. Immunol. 174: 6532-6539.
45. Presta, L. G. 2008. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20: 460-470.
46. Steinitz, M., G. Klein, S. Koskimies, and O. Makel. 1977. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269: 420-422. (Pubitemid 8232781)
47. Keller, M. A., and E. R. Stiehm. 2000. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13: 602-614.
48. Piedra, P. A., A. M. Jewell, S. G. Cron, R. L. Atmar, and W. P. Glezen. 2003. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21: 3479-3482.
49. Anderson, L. J., J. C. Hierholzer, Y. O. Stone, C. Tsou, and B. F. Fernie. 1986. Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. J. Clin. Microbiol. 23: 475-480.
50. Skiadopoulos, M. H., S. Biacchesi, U. J. Buchholz, E. Amaro-Carambot, S. R. Surman, P. L. Collins, and B. R. Murphy. 2006. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology 345: 492-501.
51. Goetsch, L., H. Plotnicky-Gilquin, T. Champion, A. Beck, N. Corvaia, S. Stahl, J. Y. Bonnefoy, T. N. Nguyen, and U. F. Power. 2000. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate. Vaccine 18: 2735-2742.
52. Kallewaard, N. L., B. A. McKinney, Y. Gu, A. Chen, B. V. Prasad, and J. E. Crowe, Jr. 2008. Functional maturation of the human antibody response to rotavirus. J. Immunol. 180: 3980-3989.